The conversations of online communities

action on rxIf pharma companies do not join the digital dialogue and influence the conversation, they will lose an opportunity to shape it, and they may be put on the defensive trying to refute the statements made by those that do take part. Continue reading »

Pfizer misses the mark with humor

offthemarkPfizer is adding humor to the battle over the post-menopause prescription market. Launched last week the “Let’s talk about change” campaign is a departure from the company’s recent “Tune into Menopause” campaign that featured Kim Cattrall.  As someone who has sat in a LOT of research with women this YouTube video really misses the mark. Continue reading »

Time to ditch ROI discussions for DTC Marketing

ditchroiPOST SUMMARY: It’s hard to have a meeting to discuss new DTC marketing initiatives without the dreaded ROI discussion. I understand that the current business environment in biopharma is about creating customers, but the problem is that consumers today don’t want to be sold.  If you really want to closer to your customers, find ways to help them make better healthcare decisions and get good credible health information. Continue reading »

Pharma knows you better than you think

imYLDb8xkhyoPOST SUMMARY: Drugmakers and Internet companies are quietly joining forces to link U.S. pharmacy records with online accounts to target ads to people based on their health conditions and the prescription drugs they buy but what do patients have to say? Continue reading »

Rapid growth in biopharma: Challenges and opportunities

screenshot_111Large-scale biotech-manufacturing facilities require $200 million to $500 million or more to build, compared with similar-scale small-molecule facilities that may cost just $30 million to $100 million, and they can take four to five years to build. It’s by far the fastest-growing part of the industry: biopharma’s current annual growth rate of more than 8 percent is double that of conventional pharma, and growth is expected to continue at that rate for the foreseeable future. Continue reading »

The mobile health hype

mhealth hypePOST SUMMARY: Dr. Joseph Kvedar, director of the Center for Connected Health at Boston-based Partners HealthCare said that nobody has figured out how to make consumers — patients — care about mobile health technologies. “And if we don’t [figure that out], m-health will be another tech bubble,” Kvedar was quoted as saying. Continue reading »

Text messaging for compliance?

drugssmallPOST SUMMARY: While mobile is on fire as a way to access the Internet and to check email and message friends suggesting that text messaging can increase compliance may not be the answer for your product. Continue reading »